Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Mol Carcinog. 2021 Mar 15;60(5):297–312. doi: 10.1002/mc.23289

FIGURE 7.

FIGURE 7

CCL5 treatment increases anoikis resistance. A, Transcript levels of CCL5 in left ovary (n=7), right ovary (n=6), ascites (n=5), omentum (n=7) and peritoneum (n=5) were compared. B, Protein expression of SDC4 in different ovarian cancer cell lines (SKOV3, Kuramochi, PA1 and ES-2). α-tubulin was used as a loading control. C, Microscopic images of attached cells or aggregates/spheroids of ovarian cancer cell lines with or without 50 ng/mL CCL5 treatment for 24, 48 and 72h. Length of the scale bar is 100 μm. D, Diameters of randomly chosen tumor spheroids were measured using ImageJ software (30–80 spheroids per group). E, PARP-1 cleavage was determined by western blotting analysis in different culture conditions of ovarian cancer cells with or without CCL5 (50 ng/mL, 72h) treatment. Values were presented as mean ± SEM. *P<0.05, **P<0.005, ***P<0.001